Krakow, Poland –  October 15, 2020 – Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, announced today that its abstract regarding the STING agonists program has been accepted for presentation at the upcoming Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020) which will take place November 9-14, 2020.

The abstract will be presented during the virtual poster session on November 11-14 from 9.00 AM till 5.00 PM.

Title: Development of improved small molecule STING agonists suitable for systemic administration

Abstract ID: 414

To view this abstract, please visit: https://www.sitcancer.org/2020/abstracts/abstract-information

The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting (SITC 2020) will be held as an entirely virtual experience this year to ensure the health and safety of attendees and their patients. SITC 2020 provides a multidisciplinary educational and interactive environment focused on improving cancer patient outcomes by incorporating strategies based on basic and applied cancer immunotherapy.